Two Different Doses of Intravitreal Bevacizumab for Treatment of Choroidal Neovascularization Associated with Age-related Macular Degeneration.

J Ophthalmic Vis Res · 2008 · PMC3589230 · PMID 23479531

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

5 6 In recent years there has been an increasing trend toward intravitreal injection of VEGF inhibitors for treatment of exudative maculopathy and the outcomes have been relatively favorable as compared to other treatment modalities. 7 – 15 Currently, two closely related anti-VEGF agents, bevacizumab and ranibizumab (both from Genentech Inc., South San Francisco, CA, USA), are used for treatment of neovascular AMD.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.